Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Cassava investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securitie

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

Boston, Massachusetts--(Newsfile Corp. - August 25, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. On August 25, 2021, Bloomberg reported that shares of Cassava were down over 20% in pre-market trading "after a lawyer asked the FDA to halt the company's clinical trials of an experimental drug, citing concerns about the...

Shareholder Alert: Berman Tabacco Announces Investigation of Cassava Sciences, Inc. (SAVA) for Potential Securities Law Violations

GameStop

NuCana

Electrameccanica

trivago

Verb Technology Company Inc

Alkaline Water Company Inc (The)

The risk in these inexpensive bargain stocks is offset by their upside for investors looking for a little more spice in their portfolio. The post 7 Bargain Stocks to Buy Under $5 With the Right Catalysts appeared first on InvestorPlace.

7 Bargain Stocks to Buy Under $5 With the Right Catalysts

Cassava Sciences Inc (NASDAQ: SAVA) reached an SPA (Special Protocol Assessment) agreement with the U.S. FDA on Tuesday morning for the phase 3 trial of its Alzheimer's treatment, Simufilam. Shares of the company, however, tanked about 30% this morning on a statement of concern that raised a question on the integrity of western blot analyses […] The post Here's why Cassava Sciences stock tanked 30% Wednesday morning appeared first on Invezz.

Here's why Cassava Sciences stock tanked 30% Wednesday morning

SAVA stock is up as the company announced the FDA has agreed on study protocols for Phase 3 clinical trials of Simufilam. The post Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near appeared first on InvestorPlace.

Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near

Neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) saw both sides of the world Tuesday. The stock rallied to close higher by 2% after it announced an agreement with the Food and Drug Administration regarding two late-stage studies of its lead drug candidate simufilam in Alzheimer's disease.

Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy

Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower on negative claims that were posted online yesterday after market hours. The company issued a response to the claims today, saying they believe the claims regarding scientific integrity are false and misleading.

Why Cassava Sciences' Stock Is Getting Hammered Today

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) fell by over 20% pre-market. This is why it happened.

SAVA Stock: Over 20% Decrease Pre-Market Explanation

Cassava Sciences Inc. SAVA, +1.92% responded Wednesday to allegations posted overnight regarding the "accuracy and integrity" of trial data for its treatment of Alzheimer's disease, saying it believed the claims are "false and misleading." Cassava's stock had rallied 1.9% on Tuesday, and 16.4% over the past three days, with the company saying early Tuesday that it reached agreement with the Food and Drug Administration under a Special Protocol Assessment (SPA) for its Phase 3 studies of oral simufilam for the treatment of Alzheimer's patients.

Cassava Sciences stock tumbles, and company responds to allegations disputing trial data

AUSTIN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today issued a response to claims that were posted on-line yesterday after market hours. Cassava Sciences believes the claims made in this post regarding scientific integrity are false and misleading. The Company stands behind its science, its scientists and its scientific collaborators, and is responding to ensure the facts are known and respected.

Cassava Sciences Responds to Allegations

BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #ClassAction--Law Offices of Howard G. Smith Announces Investigation of Cassava Sciences, Inc. (SAVA)

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

It would be great if Cassava Sciences' treatment for Alzheimer's disease worked, but should you pay the high price for SAVA stock? No. The post Cassava Sciences Has an Admirable Goal at Too High a Price appeared first on InvestorPlace.

Cassava Sciences Has an Admirable Goal at Too High a Price

Cassava Sciences Inc (NASDAQ: SAVA) announced an agreement with the FDA under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 trials for oral simufilam in treating Alzheimer's disease. The SPA document indicates that the regulator has reviewed and agreed to the critical design features of the trial protocols, the company said.

Cassava Sciences Receives FDA's Special Protocol Assessment For Alzheimer's Trials

AMC Entertainment

Express

Support.com

Vertex Energy

Hot Penny Stocks That Scored Huge For Traders In 2021 The post 5 Penny Stocks That Turned $2,500 Into Over $29,000 In 2021 So Far appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks That Turned $2,500 Into Over $29,000 In 2021 So Far

Phase 3 Study Initiation Still Expected Fall 2021 Phase 3 Study Initiation Still Expected Fall 2021

Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer's Disease

With more than 6 million people in the U.S. suffering from Alzheimer's disease, SAVA stock has enormous potential for future profits. The post Soaring Cassava Sciences Stock Shows Unfettered Promise for Growth appeared first on InvestorPlace.

Soaring Cassava Sciences Stock Shows Unfettered Promise for Growth

While SAVA stock is intriguing based on the underlying Alzheimer's treatment proposal, this market has an extremely high failure rate. The post Tread Carefully Before Pulling the Trigger on Cassava Sciences appeared first on InvestorPlace.

Tread Carefully Before Pulling the Trigger on Cassava Sciences

Given it's at risk of a severe pullback if it stumbles going forward? If you own, take some risk off the table, by partially paring down your position.

Cassava Sciences Stock Has Had an Epic Run, but Getting in Now Is a Serious Risk

At the moment, there's no cure for Alzheimer's, but Cassava Sciences is working to wipe it out for good making SAVA stock a buy here. The post These Are the Top Reasons You Should Load Up on Cassava Sciences Stock appeared first on InvestorPlace.

These Are the Top Reasons You Should Load Up on Cassava Sciences Stock

Incredible Alzheimer's data suggests that Cassava has the right approach to tackling the disease powering SAVA stock The post With This Exciting Alzheimer's Treatment, Cassava Sciences Stock Has Legs appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar

With This Exciting Alzheimer's Treatment, Cassava Sciences Stock Has Legs

Skeptics are wrong about Cassava's Alzheimer's drug, as the drug's data is superb. Long-term investors should buy SAVA stock.

Cassaca Sciences Stock Is a Buy on the Strength of a Promising Alzheimer's Drug

Alzheimer's research has been hampered by apparently mistaken ideas about what causes the disease. Cassava has a new theory about what's responsible -- and its drug is showing positive results.

Why Might Cassava Succeed With Its Alzheimer's Drug, When So Many Have Failed?

Biogen

The answer is more complicated than you think.

How Much Should An Alzheimer's Drug Cost?

Cassava Sciences has a promising drug candidate for Alzheimer's. However, SAVA stock may be overpriced based on the limited data so far.

News for Cassava Sciences Inc Stock (SAVA)